Evidence map›Paper›PMID 42430563›Full record

ArticleCancer research2026

Comprehensive Genomic Analysis of Normal and Cancer Cells Elucidates the Elevated Mutational Burden in Cancer.

Sophie Pénisson, Kameron Bates, Kunjur Manasa Upadhyaya, Kamel Lahouel, Mete Mülazımoğlu, Louka Monteiro de Sousa, Isaac Kohane, Jeffrey M Trent, Bert Vogelstein, Cristian Tomasetti

Abstract read
In one paragraph

Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sophie PénissonCenter for Cancer Prevention, Early Detection and Monitoring, City of Hope, Duarte, California.ORCID 0000-0002-6268-3842
Kameron BatesCenter for Cancer Prevention, Early Detection and Monitoring, City of Hope, Duarte, California.ORCID 0009-0003-5409-3193
Kunjur Manasa UpadhyayaCenter for Cancer Prevention, Early Detection and Monitoring, City of Hope, Duarte, California.ORCID 0009-0004-0855-7177
Kamel LahouelCenter for Cancer Prevention, Early Detection and Monitoring, City of Hope, Duarte, California.ORCID 0000-0002-4339-5749
Mete MülazımoğluCenter for Cancer Prevention, Early Detection and Monitoring, City of Hope, Duarte, California.ORCID 0009-0001-0120-5054
Louka Monteiro de SousaDepartment of Mathematics, École Normale Supérieure de Rennes, Bruz, France.ORCID 0009-0000-8248-1140
Isaac KohaneDepartment of Biomedical Informatics, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-2192-5160
Jeffrey M TrentDivision of Mathematics for Cancer Evolution and Early Detection, Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope, Duarte, California.ORCID 0000-0003-0183-4202
Bert VogelsteinLudwig Center and Lustgarten Laboratory, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland.ORCID 0000-0003-0766-3854
Cristian TomasettiCenter for Cancer Prevention, Early Detection and Monitoring, City of Hope, Duarte, California.ORCID 0000-0003-3277-4804

Funding

Blood-Based Testing for Advanced AdenomaU01CA271884 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ROBERT E. SCHOEN, Cristian Tomasetti · 2022 to 2026
$4.6M
City of Hope (Los Angeles Sanatorium) Robert & Lynda Carter Altman Family Foundation Research FundJohn Templeton Foundation (JTF) 62818National Cancer Institute (NCI) U01CA271884NCI NIH HHS U01 CA271884Virginia G. Piper Charitable Trust (Piper Trust) TGen3003979
6 · The paper itself

Abstract

Self-renewing normal tissues generate several somatic mutations at each division. Previous studies have reported that cancer cells have more mutations than their normal counterparts. It is not obvious why dramatic differences in mutational burdens between normal tissues and cancers should exist. To fully understand human tumorigenesis, the increase in mutational burden across cancers will have to be understood. In this study, we provided a systematic comparison of mutational burdens in normal and cancer cells from 5 different organs, revealing a 4-fold increase in mutational burden in cancerous versus noncancerous cells. Three proposed hypotheses could account for the increased mutational burdens in cancer: the classical hypothesis, in which driver gene mutations explain the higher mutational burden; the catastrophic hypothesis, in which extreme mutational events lead to large-scale genomic alterations; and the tail hypothesis, in which differences in baseline mutation rates among individuals account for the differences. Testing through orthogonal observations showed that the observed medians and distributions of mutational burdens in cancers could be explained by the hypotheses to various degrees of significance, and only the tail hypothesis could easily explain the increase in median mutational burdens in the normal tissues of patients with cancer compared with the normal tissues of noncancer patients. Overall, this study characterizes an increased mutational burden across multiple types of cancer compared with normal tissue and provides insights into the contributing factors. A tenable hypothesis proposed in this study involving fundamental differences in baseline mutation rates among individuals could have implications for cancer prevention strategies. SIGNIFICANCE: Comprehensive analysis of mutation burden distributions across normal and cancerous tissues reveals consistently higher burden in cancers, with a proposed explanation that may improve risk prediction and cancer prevention.

Indexed as

GenomicsMutationNeoplasmsHumansMutation Rate

Identifiers

PMID42430563
PMCPMC13612147

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.